Sun Pharma shares in focus after USFDA nod for next-gen skin disorder device
Live Events
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
Shares of Sun Pharmaceutical Industries are set to be in focus on Monday after the company announced that it had received approval from the U.S Food and Drug Administration (USFDA) for its next-generation BLU-U Blue Light Photodynamic Therapy (PDT) device, developed for the treatment of actinic keratosis—a precancerous skin condition.In a stock exchange filing on Friday, Sun Pharma said the USFDA had approved its upgraded PDT system under the agency's Real-Time Review Program. The device treats actinic keratoses, or AKs, in combination with LEVULAN® KERASTICK®—a liquid containing aminolevulinic acid that is used to target minimally to moderately thick lesions on the face, scalp, and upper extremities.According to the U.S. National Center for Biotechnology Information (NCBI), actinic keratosis is often associated with chronic sun exposure, (and) individuals with actinic keratosis may present with irregular, red, scaly papules or plaques on sun-exposed regions of the body. The condition can progress to skin cancer if left untreated.Sun Pharma's upgraded BLU-U device replaces the older fluorescent-tube-based model with modern LED technology, making it 'more compact and easier to use,' the company said.'We are pleased to receive the FDA's approval of LED BLU-U and look forward to seeing the positive impact this next generation device will have for those living with actinic keratosis,' said Abhay Gandhi, chief executive officer at Sun Pharma (North America).'As a company committed to innovation, we are confident that this new LED BLU-U model will provide improved efficiency and reliability while maintaining the safety and efficacy that healthcare professionals and people with AKs have come to trust from Sun Pharma,' Gandhi added.The company's stock has gained 13% over the past year and 2% in the past three months, though it declined 0.6% over the last week.On the technical front, Sun Pharma shares are currently trading below six of their eight key simple moving averages, including the 10-day, 20-day, 30-day, 100-day, 150-day, and 200-day SMAs. The 14-day Relative Strength Index (RSI) stands at 47.7, suggesting a neutral trend.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Hindustan Zinc declares Rs 10 interim dividend. Check record date
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Economic Times
an hour ago
- Economic Times
Nifty target 26,300 through summer; 3 sectors to lead rotation: Laurence Balanco
Live Events You Might Also Like: Nifty to climb new high by Sept-Oct; bullish on 3 stocks now: Dharmesh Shah You Might Also Like: Nomura lifts Nifty target price by 1,170 points, unveils 17 top stock picks (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel , Technical Analyst,, anticipates new highs for the Nifty , targeting 26,300 by summer, followed by a potential consolidation and a move towards 37,000. The market is experiencing rotation into lagging spaces like smallcaps, increasing participation breadth. Financials remain a key leader in the structural uptrend , with real estate and PSUs also expected to contribute to sector rotation : We have seen the rest of the world outperform the US since the April low. So, despite the S&P having a meaningful rebound, it really has been the rest of world indices from the ASX 200 to the DAX outperforming the US and you can throw the breakdown in the US dollar as an additional factor generating this relative outperformance. We still see positive price action in the Nifty. The Nifty itself has completed this double bottom pattern that trades back to 26,300. So, new highs for the Nifty is what we are looking the short term, we can see a bit more of a consolidation, but it does not take away the fact that the double bottom pattern still gives you this upside target of just over 26,300 and so there will be new highs for the in the US market particularly and in the local Indian market also, we have seen some rotation into lagging spaces. Last week, we highlighted the smallcap index which has started to accelerate higher and play catchup after underperforming since peaking in December. We have got a few of these catchup trades starting to develop and that should increase the participation breadth for this advance that we have seen in the just going back to that dollar index commentary, the break of 100 we think is meaningful, not only does it end the trading range that you had from 2022, but we think it does mark the peak to the dollar bull market that you have had from the 2011 lows. So, a major trend reversal is playing out. The breakdown from that 2022 to 2025 trading range with the break below 100 gets the dollar index down to the 89 to 90 think at least another 9% downside is likely in the dollar. Historically, we have seen that a weaker dollar has been positive for all the broader emerging market index. The EM versus DM ratio bottomed in December. We have not made any new relative lows. It does look like we are retracing against a trend of underperformance that we have seen over the past 15 years. We really think we are at the beginning of a re-rating in the emerging market basket. While India has not been a top performer year to date, we still think it is going to be one of the top performing or better performing emerging markets and our longer-term upside target for the Nifty still sits at over 37,000. So, the trend is there and continues to would not be surprised through the summer months that we get above the 26,300, then potentially see another consolidation period and then step towards that 37,000 area. But yes, the first target we will be focusing on is at 26,300 through the have seen a rotation into the laggards right now. We have seen it in the US where the stocks that have performed the worst over the past 12 months have outperformed the best performing stocks over the past 12 months and that has only happened in June. We have seen it in the local market. We are starting to see it in a bit of China too. So, this is a bit of a rotation theme that we are seeing we do not think there is a change in leadership as the leadership within the Indian market will remain centred around the financials, the underperforming spaces in IT, pharma, and FMCG are likely to continue. But outside of this short-term rebound and rotation into laggards, the structural uptrend from financials is intact and into that 37,000 target that we have, financials will be a key leader.: Probably the most recent one that looks very enticing here is still the real estate space. It is not just DLF that we have seen lead, but we have started to see some of the laggards within that come through. So, I definitely highlight real estate as a leadership sector coming through. And then, more broadly the PSU. So, not just PSU banks, but we are starting to see other PSUs also participate and recover, having peaked in July last year, having been the first major sector to have peaked last year, that started to base out and break through that downtrend resistance. So, we would put the PSUs as participating and driving some leadership now.
Time of India
2 hours ago
- Time of India
$1 Trillion GDP Boost in Sight: Abhishek Banerjee on promising sectors, gold and market sentiment
As global macroeconomic cues continue to shape market sentiment, ET Markets' Neha Vashishth Mahajan sat down with Abhishek Banerjee, CEO & Founder of LotusDew Wealth, to decode key global trends like interest rates, inflation, China's disinflation, and Donald Trump's tariff bombshell. Banerjee also shared his outlook on Indian equity markets, sectoral opportunities, and why microcaps remain a compelling space despite volatility. EXCERPTS Q. Interest rates are coming down globally. What impact do you see on Indian stocks, and how do global developments factor in? Abhishek Banerjee: Interest rates reflect both economic activity and global trade dynamics. Right now, trade is facing uncertainty due to tariffs and supply chain disruptions. Companies are unsure whether to delay procurement or over-order in anticipation of rising costs. This creates volatility, slowing trade, reducing the velocity of money, and putting mixed pressures on inflation. Some firms are pre-ordering large shipments, such as Apple, to hedge against future tariffs. But overall, we're seeing a slowdown in global demand and production. This gives central banks more room to cut interest rates. Today, most central banks are turning dovish, inclined to cut rates rather than raise them. The European Central Bank announced a cut, RBI too cut the repo rates. For equities, lower interest rates are positive. They reduce the discount rate used in stock valuations, which boosts prices, especially for high P/E, growth-oriented stocks. India, being a growth market, is likely to benefit more from this trend. Smaller and high-growth companies could outperform in a falling interest rate environment. Q. Gold prices have surged recently. Traditionally, gold rises when equities fall—but lately, both have been moving up together. Why is this happening, and what's your outlook? Abhishek Banerjee: Earlier, gold and equities were uncorrelated. Now, they're moving in tandem largely because central banks are buying gold as a reserve instead of US dollars. That's putting upward pressure on bullion. Some experts, including prominent investors and even Goldman Sachs, predict gold could touch $4,000–$5,000. I don't share that view. I believe gold has already peaked. Instead, I'm more bullish on silver, which has industrial uses—especially in EVs and electronics. Gold is more of a store of value and is driven by sentiment, while silver is increasingly relevant for future-facing industries. If you're looking at precious metals, silver and other rare earths have more upside potential, though access to some of these materials is still limited in public markets. Q. Donald Trump's repeated tariff announcements are shaking markets. Goldman Sachs estimates US inflation could hit 4% this year, with tariffs contributing significantly. The Fed has paused rate cuts, and US yields are already higher than most G10 nations. What's your take? Abhishek Banerjee: What's changed is perception. Earlier, Trump's tariff moves seemed calculated, even strategic—some thought Elon Musk might be influencing them. But with their differences now out in the open, that perception has shifted. People are beginning to question whether these are smart moves or simply political posturing. Importantly, the market still treats tariffs as temporary negotiating tools. But I believe they're becoming permanent. That means higher baseline prices and stickier inflation. While central banks may cut rates in the near term, we could see reversals if inflation doesn't ease. For India, though, this uncertainty presents an opportunity. We're benefitting from lower oil prices, growing exports—especially in defence and electronics—and higher tax collections. The government has offered relief to middle-income earners, and corporate balance sheets are flush with cash. India has around ₹10 lakh crore in corporate reserves, and we're beginning to see that being deployed in capex. Over the next 4–6 quarters, as that money is converted into productive assets, India could add $1 trillion to the economy—moving from a $4 trillion to a $5 trillion economy faster than expected. China's inflation has remained below 1% for over two years, despite fiscal and monetary stimulus. What's going on? Abhishek Banerjee: China's biggest growth engine—real estate—is struggling. With population growth slowing and urbanization largely complete, marginal demand is hard to stimulate. Meanwhile, China has overcapacity in manufacturing—they're extremely efficient, and there's little room left to extract more gains. While valuations looked attractive recently, it's risky—like catching a falling knife. China has fiscal and FX space to act, but they're also distracted by geopolitical tensions, trade wars, and a focus on military engagement. Amid all this, India has a relative advantage and looks far more promising for investors in the near term. Which sectors are likely to benefit in the near term? Abhishek Banerjee: Auto and consumer sectors are immediate beneficiaries. With April salary hikes and tax relief, consumers have more disposable income. That translates into car purchases, home upgrades, and premium consumption—travel, electronics, etc. Real estate could also benefit. On the flip side, pharma and IT services face headwinds. IT services in particular are under structural pressure despite some FX-driven margin improvements. Q. What's your take on microcaps? Brokerages seem bullish. Abhishek Banerjee: We've always been bullish on microcaps—they're our specialty. The SME segment alone has given 65% CAGR returns, though it's a high-risk space with some stocks losing 98% of their value while others gain 35x. It's a stock picker's market. Many smaller companies are undervalued simply because they've lacked investor attention. Now, with stretched valuations in large and midcaps, money is trickling down into these overlooked gems.
